Drugs

Enrique Grande: Cabozantinib with or without PD-1/L1 inhibitors for metastatic clear cell renal cell carcinoma

Photo generated from www.acsjournals.onlinelibrary.wiley.com

May 23, 2024, 11:26

Enrique Grande: Cabozantinib with or without PD-1/L1 inhibitors for metastatic clear cell renal cell carcinoma

Enrique Grande, Head of Oncology at MD Anderson Madrid Cancer Center, recently shared a post on X:

“Investigating cabozantinib with or without PD-1/L1 inhibitors for metastatic clear cell renal cell carcinoma after prior immunotherapy.

Results show similar time to next therapy and overall survival for both regimens, aligning with phase 3 CONTACT-03 trial results.”

Enrique Grande

Cabozantinib with immune checkpoint inhibitor versus cabozantinib monotherapy in patients with metastatic clear cell renal cell carcinoma progressing after prior immune checkpoint inhibitor

Authors: Georges Gebrael MD, Yeonjung Jo MS, Vinay Mathew Thomas MD, Haoran Li MD, PhD, Nicolas Sayegh MD, Nishita Tripathi MD, Ayana Srivastava, Blake Nordblad MSCR, Emre Dal MD, Arshit Narang MBBS, James Brundage MS, Patrick Campbell MD, Gliceida Galarza Fortuna MD, Chadi Hage Chehade MD, Benjamin L. Maughan MD, PharmD, Neeraj Agarwal MD, FASCO, Umang Swami MD, MS

Source: Enrique Grande/X

3 CONTACT-03 Cabozantinib cancer clear cell renal cell carcinoma Enrique Grande immunotherapy kidney cancer MD Anderson Madrid Cancer Center OncoDaily Oncology PD-1/L1 inhibitors

NEW PAPER ALERT: Efficacy of CDK4/6 Inhibitors and Endocrine Therapy in HR+/HER2- Advanced Breast Cancer by PAM50 Subtype: SOLTI-1801 CDK-PREDICT Results

Oncologist Near Me – Fabrice André: Leading Expert in Breast Cancer

Funding Impactful Cancer Research That Might Otherwise Go Unsupported: Ryan Schoenfeld on the Secret Behind Mark Foundation’s Success

One Hand Gives, Another Takes? Trump, Musk, Congress and Childhood Cancer Research Funding

Fabrice André has been elected as the President of the ESMO for the term 2025-2026

Special Coverage